MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.020
+1.55%
Closed 16:00 10/14 EDT
OPEN
1.288
PREV CLOSE
1.290
HIGH
1.310
LOW
1.288
VOLUME
2.06K
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.6000
MARKET CAP
47.00M
P/E (TTM)
-2.5486
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VBLT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VBLT News

  • Easy Come, Easy Go: How Vascular Biogenics (NASDAQ:VBLT) Shareholders Got Unlucky And Saw 80% Of Their Cash Evaporate
  • Simply Wall St..10/03 20:39
  • Vascular Biogenics' (VBLT) CEO Dror Harats on Q2 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.08/13 18:25
  • Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
  • Zacks.08/13 12:25
  • The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
  • Benzinga.08/13 11:25

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About VBLT

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
More

Webull offers Vascular Biogenics Ltd (VBLT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.